23 June 2021Entera Bio (ENTX.Q) Announces Excellent Topline Data for EB613, Shares…Kieran Robertson Entera Bio (ENTX.Q) has announced the final 6-month bone mineral density (BMD) results from its Phase 2 clinical trial of EB613 for the treatment of osteoporosis. “We are very…